Antihistamine Price Erosion Justifies Forced Switch – WellPoint
This article was originally published in The Tan Sheet
Executive Summary
WellPoint Health Networks is continuing its campaign to urge a forced Rx-to-OTC switch of low-and non-sedating antihistamines cetirizine, fexofenadine and desloratadine
You may also be interested in...
Wellpoint’s agency well-visit
FDA still is "actively working on" Wellpoint Health Network's petition to forcibly switch all low- and non-sedating antihistamines from prescription status, FDA promises the insurer in an Aug. 5 letter. Wellpoint urged Acting FDA Commissioner Lester Crawford, PhD, to reply to its 1998 and 2000 petitions to switch Pfizer's Zyrtec, Schering-Plough's Clarinex and Aventis' Allegra over the counter in a recent letter (1"The Tan Sheet" July 26, 2004, p. 6)...
Wellpoint’s agency well-visit
FDA still is "actively working on" Wellpoint Health Network's petition to forcibly switch all low- and non-sedating antihistamines from prescription status, FDA promises the insurer in an Aug. 5 letter. Wellpoint urged Acting FDA Commissioner Lester Crawford, PhD, to reply to its 1998 and 2000 petitions to switch Pfizer's Zyrtec, Schering-Plough's Clarinex and Aventis' Allegra over the counter in a recent letter (1"The Tan Sheet" July 26, 2004, p. 6)...
Wellpoint’s agency well-visit
FDA still is "actively working on" Wellpoint Health Network's petition to forcibly switch all low- and non-sedating antihistamines from prescription status, FDA promises the insurer in an Aug. 5 letter. Wellpoint urged Acting FDA Commissioner Lester Crawford, PhD, to reply to its 1998 and 2000 petitions to switch Pfizer's Zyrtec, Schering-Plough's Clarinex and Aventis' Allegra over the counter in a recent letter (1"The Tan Sheet" July 26, 2004, p. 6)...